
    
      By enrolling patients with small metastases of sarcoma adapted to enrolled criteria, this
      study will document for the first time the safety and the short and long term efficacy of mix
      vaccine.

      The safety will be evaluated by statistics of adverse reactions. The efficacy will be
      evaluated according to local relief degree, progress free survival (PFS) and overall survival
      (OS).
    
  